Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Sodium-glucose co-transporter inhibition in the treatment of diabetes: sweetening the pot.

× No keyword cloud information.

29 in total

Review 1. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.

Authors: Muhammad A Abdul-Ghani; Luke Norton; Ralph A Defronzo
Journal: Endocr Rev Date: 2011-05-23 Impact factor: 19.871

Review 2. Glucose handling by the kidney.

Authors: Amanda Mather; Carol Pollock
Journal: Kidney Int Suppl Date: 2011-03 Impact factor: 10.545

3. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.

Authors: Anthony H Barnett; Ambrish Mithal; Jenny Manassie; Russell Jones; Henning Rattunde; Hans J Woerle; Uli C Broedl
Journal: Lancet Diabetes Endocrinol Date: 2014-01-24 Impact factor: 32.069

Review 4. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.

Authors: Steven E Nissen; Kathy Wolski
Journal: Arch Intern Med Date: 2010-07-26

5. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials.

Authors: M Monami; C Nardini; E Mannucci
Journal: Diabetes Obes Metab Date: 2013-12-29 Impact factor: 6.577

6. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models.

Authors: Yoshikazu Fujimori; Kenji Katsuno; Ikumi Nakashima; Yukiko Ishikawa-Takemura; Hideki Fujikura; Masayuki Isaji
Journal: J Pharmacol Exp Ther Date: 2008-06-26 Impact factor: 4.030

7. Glucose control and vascular complications in veterans with type 2 diabetes.

Authors: William Duckworth; Carlos Abraira; Thomas Moritz; Domenic Reda; Nicholas Emanuele; Peter D Reaven; Franklin J Zieve; Jennifer Marks; Stephen N Davis; Rodney Hayward; Stuart R Warren; Steven Goldman; Madeline McCarren; Mary Ellen Vitek; William G Henderson; Grant D Huang
Journal: N Engl J Med Date: 2008-12-17 Impact factor: 91.245

8. Effects of intensive glucose lowering in type 2 diabetes.

Authors: Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald
Journal: N Engl J Med Date: 2008-06-06 Impact factor: 91.245

Review 9. Third-line agent selection for patients with type 2 diabetes mellitus uncontrolled with sulfonylureas and metformin.

Authors: Krystal L Edwards; Carlos Alvarez; Brian K Irons; Jessica Fields
Journal: Pharmacotherapy Date: 2008-04 Impact factor: 4.705

Review 10. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.

Authors: Eiji Kurosaki; Hideaki Ogasawara
Journal: Pharmacol Ther Date: 2013-04-04 Impact factor: 12.310

1 in total

1. Effect of Cichorium intybus L. seed extract on renal parameters in experimentally induced early and late diabetes type 2 in rats.

Authors: Yasin Pourfarjam; Lotfollah Rezagholizadeh; Azin Nowrouzi; Alipasha Meysamie; Sarah Ghaseminejad; Nasrin Ziamajidi; Davood Norouzi
Journal: Ren Fail Date: 2016-11-16 Impact factor: 2.606

1 in total